Search research articles
Contact Us
Filters
Showing results (831-840 of 1,098) with videos related to
Page
of 110
Sort By:
British Journal of Clinical Pharmacology
|
April 19, 2003
Undertreatment of hypercholesterolaemia: a population-based study
A K Mantel-Teeuwisse, W M M Verschuren, O H Klungel, et al.
Drug Safety
|
September 4, 2010
Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase
Thijs J Giezen, Aukje K Mantel-Teeuwisse, Ronald H B Meyboom, et al.
The New England Journal of Medicine
|
June 19, 2009
Isolated familial hypogonadotropic hypogonadism and a GNRH1 mutation
Jérôme Bouligand, Cristina Ghervan, Javier A Tello, et al.
Journal of Psychiatric Research
|
October 22, 2019
Resistance training in patients with schizophrenia: Concept and proof of principle trial
I Maurus, C Mantel, K Keller-Varady, et al.
Plos One
|
January 26, 2013
Two families with normosmic congenital hypogonadotropic hypogonadism and biallelic mutations in KISS1R (KISS1 receptor): clinical evaluation and molecular characterization of a novel mutation
Frédéric Brioude, Jérôme Bouligand, Bruno Francou, et al.
Drug Safety
|
November 18, 2009
Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval
Thijs J Giezen, Aukje K Mantel-Teeuwisse, Sabine M J M Straus, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 13, 2021
Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios
Thomas F Broekhoff, Carly C G Sweegers, Eline M Krijkamp, et al.
British Journal of Clinical Pharmacology
|
September 19, 2007
Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution
Pearl D Gumbs, W M Monique Verschuren, Patrick C Souverein, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 25, 2024
Illustrating the Financial Consequences of Outcome-Based Payment Models From a Payers Perspective: The Case of Autologous Gene Therapy Atidarsagene Autotemcel (Libmeldy®)
Marcelien H E Callenbach, Daphne Schoenmakers, Rick A Vreman, et al.
The Lancet. Oncology
|
January 14, 2016
Barriers to access to opioid medicines: a review of national legislation and regulations of 11 central and eastern European countries
Marjolein J M Vranken, John A Lisman, Aukje K Mantel-Teeuwisse, et al.
Page
of 110
Search research articles
Search
Showing results (831-840 of 1,098) with videos related to
Sort By:
Page
of 110
British Journal of Clinical Pharmacology
|
April 19, 2003
Undertreatment of hypercholesterolaemia: a population-based study
A K Mantel-Teeuwisse, W M M Verschuren, O H Klungel, et al.
Drug Safety
|
September 4, 2010
Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase
Thijs J Giezen, Aukje K Mantel-Teeuwisse, Ronald H B Meyboom, et al.
The New England Journal of Medicine
|
June 19, 2009
Isolated familial hypogonadotropic hypogonadism and a GNRH1 mutation
Jérôme Bouligand, Cristina Ghervan, Javier A Tello, et al.
Journal of Psychiatric Research
|
October 22, 2019
Resistance training in patients with schizophrenia: Concept and proof of principle trial
I Maurus, C Mantel, K Keller-Varady, et al.
Plos One
|
January 26, 2013
Two families with normosmic congenital hypogonadotropic hypogonadism and biallelic mutations in KISS1R (KISS1 receptor): clinical evaluation and molecular characterization of a novel mutation
Frédéric Brioude, Jérôme Bouligand, Bruno Francou, et al.
Drug Safety
|
November 18, 2009
Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval
Thijs J Giezen, Aukje K Mantel-Teeuwisse, Sabine M J M Straus, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 13, 2021
Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios
Thomas F Broekhoff, Carly C G Sweegers, Eline M Krijkamp, et al.
British Journal of Clinical Pharmacology
|
September 19, 2007
Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution
Pearl D Gumbs, W M Monique Verschuren, Patrick C Souverein, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 25, 2024
Illustrating the Financial Consequences of Outcome-Based Payment Models From a Payers Perspective: The Case of Autologous Gene Therapy Atidarsagene Autotemcel (Libmeldy®)
Marcelien H E Callenbach, Daphne Schoenmakers, Rick A Vreman, et al.
The Lancet. Oncology
|
January 14, 2016
Barriers to access to opioid medicines: a review of national legislation and regulations of 11 central and eastern European countries
Marjolein J M Vranken, John A Lisman, Aukje K Mantel-Teeuwisse, et al.
Page
of 110